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Pulmonary rehabilitation (PR) is part of the recommended management 
plan of pulmonary hypertension (PHTN) and is important to better quali-
ty of life and exercise tolerance. This study aimed at determining effec-
tiveness of PR on exercise capacity. Retrospective chart analysis was 
conducted on patients referred to our PHTN clinic for PR. Patients who 
had PHTN diagnosed on right heart catheterization (defined by mean 
pulmonary artery pressure> 25 mmHg) and completed a standardized 
12-week PR program were considered for the study. Patients’ baseline 
exercise tolerance was recorded as speed attainable on a treadmill 
and duration of exercise in minutes. Demographics, age, sex, and oxy-
gen use were obtained from chart review. Eighteen PHTN patients (5 
male, 13 female; mean age 67.7± 11.6 years) were considered for the 
study (six World Health Organization [WHO] group 1 pulmonary arterial 
hypertension [33.33%], eight WHO group III PHTH [44.44%], two WHO 
group IV and two WHO V PHTN [11.11%]). Treadmill speed improved 
following rehabilitation (1.3 mph [interquartile range {IQR}, 1.0–1.8 mph] 
to 2.2 mph [IQR, 1.3–2.8 mph]; P< 0.0001, Wilcoxon signed rank test). 
Median exercise time improved (27 min (IQR, 22–30 min) to 30 min (IQR, 
24–30 min); not significant. Improvement was defined only as an in-
crease in speed or duration, or both. Sixteem of 18 participants im-
proved (88.9% [95% exact binomial confidence interval, 65.3%–98.6%). 
Patients with PHTN benefit from a structured PR program to improve 
their exercise capacity and should be enrolled in PR programs as part 
of their management.
Keywords: Pulmonary hypertension, Pulmonary rehabilitation, Pulmonary 
arterial hypertension, Treadmill speed, Exercise tolerance
INTRODUCTION
Pulmonary hypertension (PHTN) is a rare and devastating dis-
ease characterized by progressive increases in pulmonary arterial 
pressure and pulmonary vascular resistance which eventually leads 
to right ventricular failure and death (Badesch et al., 2009; Farber 
and Loscalzo, 2004). It may due to various etiologies such as left 
heart disease, parenchymal lung disease, chronic thromboembolic 
disease, hematologic disorders or it may be idiopathic in nature 
though the clinical picture of these patients is similar (Simonneau 
et al., 2013). Patients with and advanced lung disease such as 
PHTN face symptomatology consistent with oxygen deprivation, 
including dyspnea, fatigue and exercise intolerance. Pulmonary 
rehabilitation (PR) in patients with PHTN patients is in fact im-
portant in the management as it improves outcomes (Sahni et al., 
2015). This study is aimed at determining the effectiveness of 
structured PR program on exercise capacity in a population of 
PHTN patients.
MATERIALS AND METHODS
Study population and design
We conducted a retrospective review of data collected on 18 pa-
tients with diagnosis of PHTN who participated in the Northwell 
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Health PR program. For the purposes of the study PHTN was 
defined in accordance to the most updated guidelines of the 
American College of Chest Physicians and the European Respira-
tory Society (Galie et al., 2015). PHTN was defined hemodynam-
ically as a mean resting pulmonary artery pressure greater than or 
equal 25 mmHg and pulmonary arterial hypertension (PAH) was 
a pulmonary artery wedge pressure less than or equal to 15 
mmHg on right heart catheterization (Galie et al., 2015). As the 
World Health Organization (WHO) has proposed a classification 
system for PHTN based on common clinical features and etiology 
which has been outlined in Table 1 (Simonneau et al., 2013). Our 
patients were categorized into WHO groups of PHTN based on 
underlying etiology of PHTN and completed a standardized 12-
week PR program to be considered for the study. 
Pulmonary rehabilitation
All patients considered for the study completed our PR pro-
gram. The PR program at our center has been certified by the 
American Association of Cardiovascular and Pulmonary Rehabili-
tation and is designed towards adult patients with chronic lung 
disease or patients preparing/recovering from lung surgery. The 
program consists of an exercise and education component with 
three sessions weekly over a period of 12-week period. Following 
the completion of the 12-week program, maintenance sessions are 
also available for patients to participate.
The rehab facility at our site is equipped with exercise equip-
ment such as treadmill, upper/lower body recumbent stepper (Nu-
Step LLC, Ann Arbor, MI, USA), arm ergometers and free weights. 
In addition, safety equipments available include: electrocardiogram 
monitoring, pulse oximetry, blood pressure monitoring and sup-
plemental oxygen. The education component consists of biweekly 
educational lecture series that comprise of breathing techniques 
along with stress and relaxation exercises. As part of our PR pro-
gram all patients are asked to fill out quality of life, fatigue and 
sleep questionnaires before and after completion of the program.
At the time of the enrollment in PR, all patients were clinically 
stable, and all were receiving optimal medical therapy. Patients’ 
baseline exercise tolerance was recorded as speed attainable on a 
treadmill in miles per hour (mph) and duration of exercise in min-
utes (min). Demographics, age, sex, New York Heart Association 
functional class and oxygen use were obtained from chart review. 
Data were analyzed using SAS ver. 9.3 (SAS Institute Inc., Cary, 
NC, USA). The change in each component of the treadmill exercise 
(speed, grade, duration), was examined using the Wilcoxon signed 
rank test. Improvement was defined as an increase in speed or dura-
tion (or both), with no decrease in either component). The percent 
of subjects who improved based on this definition was then calcu-
lated, along with the associated exact binomial 95% confidence in-
terval. Northwell Health System Institutional Review Board ap-
proval was obtained for this study (approval number: 14-574).
RESULTS 
Eighteen patients with PHTN met the criteria for the study. 
There were a total of 5 male and 13 female patients with a mean 
age 67.7±11.6 years. Of these patients there were six (33.33% 
who were considered WHO group 1 PAH), eight WHO group 
III PHTN (44.44%), two WHO group IV, and two WHO V 
PHTN (11.11%). Demographics have been outlined in Table 1. 
Of these patients, 14 (82.4%) were on supplemental oxygen. It 
was found that as a whole across all WHO groups of PHTN, 
treadmill speed improved following rehab (P<0.0001, Wilcoxon 
signed rank test). Median treadmill speed prior to rehab was 1.3 
mph (interquartile range [IQR], 1.0–1.8 mph) and 2.2 mph (IQR, 
1.3–2.8 mph) following rehab Fig. 1.  
Prior to rehab, median exercise time was 27 min (IQR, 22–30 
min), after rehab, median exercise time was 30 min (IQR, 24–30 
min). The total exercise time also improved though not found to 
be statistically significant. Sixteen of the 18 participants improved 
(88.9%; 95% exact binomial confidence interval, 65.3%–98.6%).
Table 1. Patient demographics (n= 18)
Demographic Value
Age (yr) 67.7± 11.6
Sex
   Male 5 (27.8)
   Female 13 (72.2)
WHO groups
I 6 (33.3)
II 0 (0)
III 8 (44.4)
IV 2 (11.1)
V 2 (11.1)
WHO functional class
I 1 (5.6)
II 7 (38.9)
III 9 (50.0)
IV 1 (5.6)
Values are presented as mean± standard deviation or number (%).
WHO, World Health Organization.
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DISCUSSION
PHTN treatment is centered on improved cardiopulmonary 
hemodynamics resulting in increased exercise tolerance as general-
ly measured by the 6-min walk test. This emerging data has been 
seen specifically in the WHO group I PAH (Babu et al., 2016; 
Chan et al., 2013). Our study shows exercise tolerance improve-
ments in terms of speed in mph and increased duration of exercise 
across multiple etiologies of PHTN after a course of structured 
PR. The results of this study also demonstrate that despite diag-
nostic etiology of PHTN and disease severity structured PR in-
creases exercise tolerance.
 The American Thoracic Society and the European Respiratory 
Society have defined pulmonary rehabilitation as an “evidence 
based, multidisciplinary and comprehensive intervention for pa-
tient with chronic respiratory diseases who are symptomatic and 
often have decreased daily life activities” (Nici et al., 2006). The 
principal purpose of PR programs is to improve function, disease 
related symptoms, optimize functional capacity and an overall 
improvement in quality of life.
The use PR as an adjuvant to pharmacotherapy is well estab-
lished (Nici et al., 2006). PR has become a staple of therapy in ad-
vanced lung disease including chronic obstructive pulmonary dis-
ease (Casaburi et al., 2005), idiopathic pulmonary fibrosis (Raghu 
et al., 2011) and PHTN (Mereles et al., 2006) amongst others. 
Early thought process of exercise in PHTN was that it may be 
harmful, expedite the disease process and may even cause sudden 
death. However, evidenced based medicine has proven the oppo-
site to be true (Sahni et al., 2015). The underlying mechanism of 
PR resulting in an increased exercise tolerance remains conjectur-
al. Disease mechanism in PHTN heavily involves endothelin-1 
(ET-1), the human body’s most potent vasoconstrictor. Studies 
have shown that chronic exercise causes an increase in the produc-
tion of nitric oxide, a potent vasodilator and a decrease in the pro-
duction of ET-1 which in turn may net a vasodilatory effect there-
by decreasing pulmonary vascular resistances, increasing cardiac 
output and increasing exercise tolerance (Maeda et al., 2001). It is 
also important to note that the overall increase of speed in our pul-
monary rehab patients points to an increase in exercise tolerance 
and endurance. Patients who were unable to increase their overall 
speed showed an increase in the duration of time there were able 
to exercise also pointing to an increased in endurance. A study by 
Otsuki et al. (2006) showed that ET-1 concentrations were lower 
in individuals who participated in strength or endurance training 
as compared to sedentary controls. As the knowledge and benefi-
cial evidence of PR steadily increases the use in PHTN patients 
should continue to become part of standard of care.
In conclusion our study was able to show that patients with all 
types of PHTN and varying WHO functional class show im-
provement as measured by speed and time from a structured PR 
program. All PHTN patients should be enrolled in PR programs 
as part of their management in adjuvant to their pharmacotherapy 
and regardless of their WHO functional class.
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